Can Semax and BPC-157 be combined?
There are no published studies directly analysing Semax and BPC-157 combined. Any answer must therefore be built upon an understanding of what each compound does on its own. This requires reasoning as to whether their mechanisms are likely to be complementary or conflicting. This is different to pointing to a study that has actually tested this combination. It can be said that both compounds act via largely different biological systems. This at least reduces the likelihood of direct pharmacological conflict. However, this is not proof that the combination is beneficial. Nor is it investigated enough to call it low risk with certainty.
BPC-157 is a synthetic peptide fragment derived from a protein found in gastric juice. It is primarily researched — outside of the Semax research collection reviewed here — for its effects on tissue healing. This includes effects on tendons, muscles, intestinal lining, and blood vessel formation. Semax, on the other hand, focuses almost entirely on the central nervous system. Its best-documented effects include increasing BDNF and NGF, neuroprotection after brain injury, and modulation of neurotransmitter systems such as dopamine, serotonin, and GABA [1], [2]. These are truly different areas of the body. One is largely peripheral tissue repair. The other is largely central nervous system function. Partly because of this, those interested in combining them typically frame the combination as addressing two distinct goals simultaneously. They generally do not expect either compound to enhance the specific effects of the other.
What are the theoretical benefits of combining Semax and BPC-157?
As no combined study exists, any discussion regarding benefits must clearly remain in the realm of theoretical reasoning. This reasoning is predicated on the individually documented properties of each compound. Consider someone dealing with a physical injury requiring tissue repair, alongside cognitive or brain-related goals. For example, someone recovering from a musculoskeletal injury while also wanting cognitive support during a demanding period. The appeal of combining the two compounds lies in addressing both needs simultaneously. Semax would focus on the brain-related goals. BPC-157 would focus on the physical side of tissue healing. This offers a sensible practical rationale. However, it is important to clearly state: this is not the same as evidence that their combination produces any effect beyond what each would do independently on its own.
It is worth mentioning one area of potential overlap. Semax has documented effects on vascular gene expression and blood flow. This includes modulation of VEGF family genes involved in blood vessel formation and repair [3]. BPC-157 is also widely discussed for its angiogenic properties in its own separate research base. If both compounds do indeed affect the processes of blood vessel formation and repair – even through different specific mechanisms – then there is at least a plausible basis to think that their effects on vascular repair could be complementary. This remains, however, entirely untested.
Are there any risks in combining Semax and BPC-157?
Without any direct investigation into the combination, the reliable answer is: the risk profile of combining these two compounds is genuinely unknown. It is neither definitively low nor high. It could be said that no individual studies of these compounds have identified obvious safety signals that would predict a dangerous interaction between them specifically. Documented risks for Semax focus on effects on blood clotting [4] and dopaminergic enhancement with stimulants [5]. Neither of these risks have obvious direct overlap with what is typically discussed in the context of BPC-157's safety profile. This lack of an obvious warning signal is reassuring in a limited way. However, it is not the same as having actual safety data for the combination. Anyone combining uninvestigated compounds should understand that they are operating without a direct evidence base in either direction.
What would the Semax and BPC-157 protocols look like?
As no formal protocol has been established or validated by research, any specific dosing schedule discussed for this combination within online communities reflects user-generated practice. This is not a scientifically derived recommendation. The most commonly discussed approach separates these two compounds by purpose, and sometimes by timing. Semax is administered intranasally for its central nervous system effects. BPC-157 is administered by its own typical route—often subcutaneous injection near a site of injury or systemically—for tissue-specific purposes. This is distinct from combining them into a single mixed preparation. Treating them as two distinct interventions addressing two distinct targets is a more scientifically sound way to conceptualise this combination. It is preferable to treating them as a single, combined concoction with its own unique synergistic effect, given the current lack of research.
Can Semax be combined with Dihexa?
No published studies have analysed Semax and Dihexa when administered together. However, there is an interesting mechanistic reason why this particular combination is so often discussed. Dihexa is a compound being studied outside of this research collection. It is known for its effects on hepatocyte growth factor (HGF) and its receptor c-Met. This is a signalling pathway involved in promoting synaptic connectivity and neuroplasticity. Semax's best-documented mechanism involves another, yet related, growth factor pathway: the upregulation of BDNF and NGF [1], [6]. One review article specifically grouped Semax and Dihexa together as neuroactive peptides. It described them as compounds that increase brain-derived neurotrophic factor and the HGF/c-Met pathways critical for neuroplasticity [7]. This suggests that researchers reviewing the broader field of peptide therapeutics perceive these two compounds as operating in a similar conceptual space. However, they operate through distinct molecular pathways—BDNF/TrkB for Semax, HGF/c-Met for Dihexa.
This type of pathway complementarity is the theoretical basis that people who combine these compounds refer to. Two different growth factor systems both converge on supporting neuroplasticity. The reasoning is that by acting to support neuroplasticity from two separate molecular angles, a broader effect may be elicited than relying on one pathway alone. This remains a reasonable hypothesis, not a demonstrated discovery. The actual combination has never been tested in any controlled study.
What are the benefits of Semax and Dihexa together?
Since this specific combination has not been investigated, any discussion of benefits describes a theoretical rationale here, not a confirmed outcome. The rationale is based on one idea. BDNF/TrkB signalling – the main documented pathway for Semax – and HGF/c-Met signalling – the main pathway investigated for Dihexa – are somewhat distinct pathways. Both ultimately support synaptic plasticity and neuronal connectivity. This suggests that combining factors acting on each pathway separately could theoretically elicit more comprehensive neuroplastic support than either alone. Whether this theoretical additive benefit actually materialises in practice, and to what extent, simply has not been tested.
Can Semax be combined with NAD+?
No published studies have analysed Semax in combination with NAD+ or NAD+ precursor compounds such as nicotinamide riboside or nicotinamide mononucleotide. These compounds act via largely distinct biological systems. NAD+ is central to cellular energy metabolism, mitochondrial function and processes like DNA repair by activating sirtuin enzymes. Semax's main documented mechanisms include neurotrophin signalling, neurotransmitter modulation and changes in gene expression related to inflammation and neuroprotection [1], [8]. This relative separation between the primary mechanisms of the two compounds suggests a lower likelihood of direct pharmacological conflict. However, it also implies a limited mechanistic basis for expecting a strong synergistic effect. Each compound would most likely simply do its own thing independently in parallel.
It is worth noting one area of potential overlap. Semax has documented neuroprotective effects on mitochondrial function during periods of calcium stress and glutamate toxicity. It delays the collapse of mitochondrial membrane potential in neurons exposed to excitotoxic conditions [9]. NAD+ is fundamentally linked to mitochondrial energy production and health. Thus, there is at least a plausible basis for thinking that combining a compound that supports mitochondrial resilience under stress (Semax) with one that directly bolsters mitochondrial metabolic capacity (NAD+) could be mechanistically complementary. This remains, however, speculative reasoning rather than evidence.
What is the combination of Semax and Cerebrolysin?
This is one of the few combinations in this article where there are real comparative studies. Even so, the two compounds were not tested together as a combined treatment. They were tested side-by-side in the same study for comparison. The researchers assessed both Cerebrolysin and Semax for their trophic effects on cultured rat pheochromocytoma (PC12) cells. They found a very significant difference between them. Cerebrolysin induced clear morphological signs of cell differentiation. It also improved cell survival under serum-free conditions, actively reducing the percentage of dying (apoptotic) cells. Semax did not induce a comparable trophic effect on these particular cells in this particular experimental context [10]. The researchers concluded that the neuroprotective effects of Cerebrolysin likely arise from direct trophic action on cells. Semax's protective effects in other contexts appear to work through entirely different mechanisms, rather than this same type of direct cellular trophic support [10].
This is a very useful finding for anyone considering this combination. It suggests that both compounds may act via significantly different, complementary mechanisms, rather than redundant ones. Cerebrolysin offers more direct cellular trophic support properties. Semax offers gene expression, neurotransmitter, and inflammation modulating effects. However, this study only compared the two compounds side-by-side in an isolated cell model. It did not test them concurrently in a living animal or human. Drawing conclusions about an actual combined protocol is still beyond what this study specifically supports.
Based on available research, which compounds work best with Semax?
Looking at all the available research, one compound stands out with the most directly relevant comparative data and combination studies: Selank. This is due to a shared research history between these two peptides. It is also due to a direct comparison study of functional connectivity conducted in the same group of healthy human volunteers [11]. Beyond Selank, the combinations discussed above — BPC-157, Dihexa, NAD+, and Cerebrolysin — all represent theoretically reasonable combinations based on complementary yet distinct mechanisms. However, none of them have actual co-administration studies behind them. The reliable overall picture is this: what works best with Semax remains largely an open question. Current research has not directly answered this for any combination beyond Semax and Selank.
What is the combination of Semax and fenbendazolu?
This is a combination that appears in certain online discussion forums. However, it is important to state this clearly and directly: there are no scientific studies linking Semax and fenbendazol in any way. These two compounds belong to entirely unrelated pharmacological categories. There is no documented common mechanism of action, shared research history or rational basis for their combination in any of the peer-reviewed literature reviewed here.
Fenbendazol is an antiparasitic drug. Specifically, it is a benzimidazole compound. It has been used in veterinary medicine to treat parasitic worm infections in animals. It acts by mechanisms involving the disruption of microtubule formation in parasites. This is a completely different class of compound to Semax. Semax is a neuroactive peptide that acts via entirely distinct biological pathways. These include neurotrophin signalling, neurotransmitter modulation and changes in gene expression in brain tissue [1], [2]. There is no overlapping mechanism between the benzimidazole antiparasitic compound and the neuroprotective peptide. There is no scientific justification whatsoever for combining them.
Dlaczego ludzie dyskutują o tej kombinacji?
The interest in fenbendazol in combination with various other compounds, including Semax, appears to stem from unrelated online discussions about fenbendazolu. These discussions circulated separately from any research context specific to Semax. They are often linked to broader and largely unsubstantiated claims about fenbendazolu in areas far beyond its established veterinary antiparasitic use. When two unrelated compounds attract attention in online wellness or biohacking circles, people commonly start discussing them together. This usually happens simply because both are discussed within overlapping communities. It does not happen because there is any actual scientific or pharmacological basis linking them.
Is it safe to combine Semax and fenbendazol?
There are no studies that directly address this question. Semax’s research portfolio covers neuroscience, neuroprotection and the physiology of stress. There is no significant overlap with veterinary antiparasitic pharmacology fenbendazolu. There is therefore no established scientific framework for assessing the specific risk of interaction between them. This does not mean that a dangerous interaction necessarily exists. It means that there is no research base from which any conclusion, positive or negative, can be drawn regarding their combination. This is a significantly different and more uncertain situation than even the other combinations discussed in this article. Those other combinations at least involve compounds with some conceptual or mechanistic link to the known effects of Semax. Fenbendazol simply lacks such a link.
What do the studies actually say about Semax and fenbendazolu?
Nothing. There are no published studies. There are no case reports. There are no animal studies. There are no clinical data of any kind analysing Semax and fenbendazol together. Any claims regarding specific effects, benefits or protocols for this combination circulating online are not supported by anything in the scientific literature. They should be treated with considerable scepticism. Given the complete lack of any scientific basis linking these two very different types of compounds, combining them would constitute a completely unstudied and unsupported practice. This remains true even by the more lenient standards applied to certain other uninvestigated combinations discussed elsewhere in this article.
Disclaimer
This content is intended solely for educational, informational and scientific purposes. It should not be interpreted as medical advice, a diagnosis or a treatment recommendation. Semax remains an investigational compound in most countries, including the United States and most European countries. It is not approved by the US Food and Drug Administration (FDA) or the European Medicines Agency (EMA) for the treatment of any medical condition. It is approved and used clinically in Russia and some Eastern European countries. None of the combinations discussed in this article — Semax with BPC-157, Dihexa, NAD+, cerebrolysin or fenbendazol — has been directly studied in humans or animals as combined protocols. The reasoning presented is based on separate studies of each individual compound, rather than on tested data for the combinations.
References
[1] Dolotov, O. V., Karpenko, E. A., Inozemtseva, L. S., Seredenina, T. S., Levitskaya, N. G., Rozyczka, J., Dubynina, E. V., Novosadova, E. V., Andreeva, L. A., Alfeeva, L. Yu., Kamensky, A. A., Grivennikov, I. A., Myasoedov, N. F., & Engele, J. (2006). Semax, an analogue of ACTH(4-10) with cognitive effects, regulates BDNF and trkB expression in the rat hippocampus. Brain Research, 1117(1), 54–60. https://doi.org/10.1016/j.brainres.2006.07.108
[2] Eremin, K. O., Kudrin, V. S., Saransaari, P., Oja, S. S., Grivennikov, I. A., Myasoedov, N. F., & Rayevsky, K. S. (2005). Semax, an ACTH(4-10) analogue with nootropic properties, activates dopaminergic and serotoninergic brain systems in rodents. Neurochemical Research, 30(12), 1493–1500. https://doi.org/10.1007/s11064-005-8826-8
[3] Medvedeva, E. V., Dmitrieva, V. G., Povarova, O. V., Limborska, S. A., Skvortsova, V. I., Myasoedov, N. F., & Dergunova, L. V. (2013). Effect of semax and its C-terminal fragment Pro-Gly-Pro on the expression of VEGF family genes and their receptors in experimental focal ischaemia of the rat brain. Journal of Molecular Neuroscience, 49(2), 328–333. https://doi.org/10.1007/s12031-012-9853-y
[4] Grigorjeva, M. E., & Lyapina, L. A. (2010). Anticoagulation and antiplatelet effects of semax under conditions of acute and chronic immobilisation stress. Bulletin of Experimental Biology and Medicine, 149(1), 44–46. https://doi.org/10.1007/s10517-010-0871-x
[5] Eremin, K. O., Saransaari, P., Oja, S., & Raevskiĭ, K. S. (2004). Semax potentiates effects of D-amphetamine on the level of extracellular dopamine in the Sprague-Dawley rat striatum and on the locomotor activity of C57BL/6 mice. Experimental and Clinical Pharmacology, 67(2), 8–11. PMID: 15188751
[6] Shadrina, M. I., Dolotov, O. V., Grivennikov, I. A., Slominsky, P. A., Andreeva, L. A., Inozemtseva, L. S., Limborska, S. A., & Myasoedov, N. F. (2001). Rapid induction of neurotrophin mRNAs in rat glial cell cultures by Semax, an adrenocorticotropic hormone analog. Neuroscience Letters, 308(2), 115–118. https://doi.org/10.1016/s0304-3940(01)01994-2
[7] Rahman, O. F., Lee, S. J., & Seeds, W. A. (2026). Therapeutic peptides in orthopaedics: Applications, challenges, and future directions. Journal of the American Academy of Orthopaedic Surgeons Global Research and Reviews, 10£25.00. https://doi.org/10.5435/JAAOSGlobal-D-25-00236
[8] Filippenkov, I. B., Stavchansky, V. V., Denisova, A. E., Yuzhakov, V. V., Sevan’kaeva, L. E., Sudarkina, O. Yu., Dmitrieva, V. G., Gubsky, L. V., Myasoedov, N. F., Limborska, S. A., & Dergunova, L. V. (2020). Novel insights into the protective properties of ACTH(4-7)PGP (Semax) peptide at the transcriptome level following cerebral ischaemia-reperfusion in rats. Genes, 11(6), 681. https://doi.org/10.3390/genes11060681
[9] Storozhevykh, T. P., Tukhbatova, G. R., Senilova, Ya. E., Pinelis, V. G., Andreeva, L. A., & Myasoyedov, N. F. (2007). Effects of semax and its Pro-Gly-Pro fragment on calcium homeostasis of neurons and their survival under conditions of glutamate toxicity. Bulletin of Experimental Biology and Medicine, 143(5), 601–604. https://doi.org/10.1007/s10517-007-0192-x
[10] Safarova, E. R., Shram, S. I., Grivennikov, I. A., & Myasoedov, N. F. (2002). Trophic effects of nootropic peptide preparations cerebrolysin and semax on cultured rat pheochromocytoma. Bulletin of Experimental Biology and Medicine, 133(4), 401–403. https://doi.org/10.1023/a:1016270626439
[11] Panikratova, Ya. R., Lebedeva, I. S., Sokolov, O. Yu., Rumshiskaya, A. D., Kupriyanov, D. A., Kost, N. V., & Myasoedov, N. F. (2020). A functional connectomic approach to studying the effects of Selank and Semax. Doklady Biological Sciences, 490(1), 9–11. https://doi.org/10.1134/S001249662001007X